Literature DB >> 15311940

CYP51 from Trypanosoma brucei is obtusifoliol-specific.

Galina I Lepesheva1, W David Nes, Wenxu Zhou, George C Hill, Michael R Waterman.   

Abstract

New isoforms of CYP51 (sterol 14alpha-demethylase), an essential enzyme in sterol biosynthesis and primary target of azole antimycotic drugs, are found in pathogenic protists, Trypanosoma brucei(TB), T. vivax, T. cruzi, and Leishmania major. The sequences share approximately 80% amino acid identity and are approximately 25% identical to sterol 14alpha-demethylases from other biological kingdoms. Differences of residues conserved throughout the rest of the CYP51 family that align with the BC-loop and helices F and G of CYP51 from Mycobacterium tuberculosis (MT)) imply possible alterations in the topology of the active site cavity of the protozoan enzymes. CYP51 and cytochrome P450 reductase (CPR) from TB were cloned, expressed in Escherichia coli, and purified. The P450 has normal spectral features (including absolute absorbance, carbon monoxide, and ligand binding spectra), is efficiently reduced by TB and rat CPR but demonstrates altered specificity in comparison with human CYP51 toward three tested azole inhibitors, and contrary to the human, Candida albicans, and MT isoforms, reveals profound substrate preference toward obtusifoliol (turnover 5.6 min(-1)). It weakly interacts with the other known CYP51 substrates; slow lanosterol conversion predominantly produces the 14alpha-carboxyaldehyde intermediate. Although obtusifoliol specificity is typical for plant isoforms of CYP51, the set of sterol biosynthetic enzymes in the protozoan genomes together with available information about sterol composition of kinetoplastid cells suggest that the substrate preference of TBCYP51 may reflect a novel sterol biosynthetic pathway in Trypanosomatidae.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15311940     DOI: 10.1021/bi048967t

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  42 in total

1.  Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14alpha-demethylase (CYP51) from Leishmania infantum.

Authors:  Tatiana Y Hargrove; Zdzislaw Wawrzak; Jialin Liu; W David Nes; Michael R Waterman; Galina I Lepesheva
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

2.  Pharmacological characterization, structural studies, and in vivo activities of anti-Chagas disease lead compounds derived from tipifarnib.

Authors:  Frederick S Buckner; Maria Terezinha Bahia; Praveen Kumar Suryadevara; Karen L White; David M Shackleford; Naveen Kumar Chennamaneni; Matthew A Hulverson; Joy U Laydbak; Eric Chatelain; Ivan Scandale; Christophe L M J Verlinde; Susan A Charman; Galina I Lepesheva; Michael H Gelb
Journal:  Antimicrob Agents Chemother       Date:  2012-07-09       Impact factor: 5.191

3.  Steroids, triterpenoids and molecular oxygen.

Authors:  Roger E Summons; Alexander S Bradley; Linda L Jahnke; Jacob R Waldbauer
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-06-29       Impact factor: 6.237

Review 4.  Sterol 14alpha-demethylase cytochrome P450 (CYP51), a P450 in all biological kingdoms.

Authors:  Galina I Lepesheva; Michael R Waterman
Journal:  Biochim Biophys Acta       Date:  2006-08-02

Review 5.  The Mycobacterium tuberculosis cytochrome P450 system.

Authors:  Hugues Ouellet; Jonathan B Johnston; Paul R Ortiz de Montellano
Journal:  Arch Biochem Biophys       Date:  2009-07-25       Impact factor: 4.013

6.  The Investigational Drug VT-1129 Is a Highly Potent Inhibitor of Cryptococcus Species CYP51 but Only Weakly Inhibits the Human Enzyme.

Authors:  Andrew G S Warrilow; Josie E Parker; Claire L Price; W David Nes; Edward P Garvey; William J Hoekstra; Robert J Schotzinger; Diane E Kelly; Steven L Kelly
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

7.  Complexes of Trypanosoma cruzi sterol 14α-demethylase (CYP51) with two pyridine-based drug candidates for Chagas disease: structural basis for pathogen selectivity.

Authors:  Tatiana Y Hargrove; Zdzislaw Wawrzak; Paul W Alexander; Jason H Chaplin; Martine Keenan; Susan A Charman; Catherine J Perez; Michael R Waterman; Eric Chatelain; Galina I Lepesheva
Journal:  J Biol Chem       Date:  2013-09-18       Impact factor: 5.157

8.  The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease.

Authors:  Oliver Hucke; Michael H Gelb; Christophe L M J Verlinde; Frederick S Buckner
Journal:  J Med Chem       Date:  2005-08-25       Impact factor: 7.446

9.  Sterol 14α-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae.

Authors:  Laura Friggeri; Tatiana Y Hargrove; Girish Rachakonda; Anna L Blobaum; Paxtyn Fisher; Gabriel Melo de Oliveira; Cristiane França da Silva; Maria de Nazaré C Soeiro; W David Nes; Craig W Lindsley; Fernando Villalta; F Peter Guengerich; Galina I Lepesheva
Journal:  J Med Chem       Date:  2018-11-30       Impact factor: 7.446

10.  Phylogenomics of sterol synthesis: insights into the origin, evolution, and diversity of a key eukaryotic feature.

Authors:  Elie Desmond; Simonetta Gribaldo
Journal:  Genome Biol Evol       Date:  2009-09-10       Impact factor: 3.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.